SYRE vs PRTA vs RCUS vs JNJ

For growth investors, Johnson & Johnson (JNJ) is the stronger pick with 4.

3% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Johnson & Johnson (JNJ) offers the better valuation at 38. 4x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Spyre Therapeutics, Inc. (SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Johnson & Johnson is actually cheaper at 19.

2x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +46.

1%, compared to -59. 6% for Spyre Therapeutics, Inc. (SYRE). Over 10 years, the gap is even starker: JNJ returned +132. 3% versus PRTA's -73. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Spyre Therapeutics, Inc. 's 2. 06β — meaning SYRE is approximately 3507% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Johnson & Johnson (JNJ) is pulling ahead at 4.

3% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Spyre Therapeutics, Inc. grew EPS 37. 7% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Johnson & Johnson (JNJ) trades at 19.

2x forward P/E versus 42. 7x for Prothena Corporation plc — 23. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 80. 4% to $19. 00.

In this comparison, JNJ (2.

2% yield) pays a dividend. SYRE, PRTA, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Spyre Therapeutics, Inc. (SYRE) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +132. 3%, SYRE: -66. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

JNJ pays a dividend while SYRE, PRTA, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.